USA — American Regent, a Daiichi Sankyo Group company has recently announced the launch of sulfite-free Epinephrine Injection, USP, which is an emergency treatment for Type I allergic reactions, including anaphylaxis.
Anaphylaxis can be triggered by various factors such as insect bites or stings, drugs, foods, sera, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
Additionally, Epinephrine injection, USP is also indicated for increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock.
The recent launch of sulfite-free Epinephrine Injection, USP by American Regent has come as a promising development for patients and healthcare providers who need to manage and treat anaphylactic reactions.
Sulfites are commonly used as preservatives in various medications, including epinephrine injections, but can cause adverse reactions in patients with sulfite sensitivity or allergy.
The sulfite-free formulation of Epinephrine Injection, USP not only ensures that patients with sulfite sensitivity or allergy can receive the medication without fear of an allergic reaction but also provides an alternative treatment option to healthcare providers.
In response to the launch of the sulfite-free Epinephrine Injection, USP, Joann Gioia, Vice President, and Chief Commercial Officer at American Regent, Inc., expressed her commitment to ensuring that patients and healthcare providers have access to quality treatment options.
With the approval of this generic alternative, American Regent has demonstrated its dedication to providing accessible, effective, and safe treatments for patients in need.
The launch of sulfite-free Epinephrine Injection, USP by American Regent has opened up new avenues for treating and managing anaphylaxis, and it is a significant step towards improving the lives of patients.
The global epinephrine market is witnessing significant growth, driven by factors such as the increasing prevalence of allergic reactions and the growing demand for emergency treatment options.
According to the Fortune Business Insights report, the market is expected to grow at a CAGR of 9.5% from 2020 to 2027.
One of the notable developments in the epinephrine market is the increasing adoption of auto-injectors.
Auto-injectors are easy-to-use devices that can be self-administered by patients, making them a convenient and effective treatment option for emergencies such as anaphylaxis.
Key players in the market, such as Mylan N.V., have launched auto-injector products such as EpiPen and EpiPen Jr.
These products have gained widespread acceptance, with many schools, universities, and workplaces requiring their availability for emergency situations.
Partnerships and collaborations have also played a significant role in driving the growth of the epinephrine market.
For example, in 2019, Adamis Pharmaceuticals Corporation signed a distribution agreement with Sandoz Inc., a division of Novartis, for its Symjepi product. The agreement helped expand the availability of Symjepi to patients in the United States.
Similarly, in 2020, Teva Pharmaceutical Industries Ltd. signed an agreement with Antares Pharma Inc. to distribute the latter’s epinephrine auto-injector product, XYMELA, in the United States.
Key players in the epinephrine market include Pfizer Inc., Mylan N.V., Kaleo, Inc., Amphastar Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd., and Impax Laboratories Inc.
These players have a strong market presence and are constantly engaged in research and development to develop innovative products and expand their market share.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
